am -
pm ET

Frequently Asked Questions (FAQs)

What is Alnylam Assist™?

Alnylam Assist™ is a comprehensive patient support program that offers truly personalized assistance for patients getting started on treatment with OXLUMO® (lumasiran) or other Alnylam products. Each patient prescribed an Alnylam therapy is assigned a dedicated Case Manager as a primary point of contact and will also be connected with a Patient Education Liaison (PEL). The program is designed to provide ongoing support throughout treatment that’s easy for patients and their families to access and adapts as those needs may change. See how Alnylam Assist can support you throughout treatment ›

How do I get started in the Alnylam Assist™ program?

In order to enroll in the program, you must be prescribed OXLUMO and fill out the Start Form with your doctor. Once the form is completed and you've signed it, your doctor can submit the form online or print it out and fax it to Alnylam Assist™. Find out more about getting started ›

What services does Alnylam Assist™ offer?

Alnylam Assist™ focuses on 3 key areas of support and services for patients and their families: insurance benefit verification, financial assistance options for eligible patients, and disease and treatment education. Within each of these key areas are benefits and services to surround patients and their families with ongoing support during treatment. Find out more about the support and services offered ›

Who are Case Managers?

Case Managers are experienced in helping individuals get started on treatment and providing ongoing support. They will tailor their level of contact based on your personal needs. Your Alnylam Case Manager can help you understand your insurance coverage for OXLUMO and your options for financial support that you may be eligible for, as well as provide you with educational resources. Learn how you can work together with your own personal Case Manager ›

Who are Patient Education Liaisons (PELs)?

PELs have backgrounds in nursing and are experienced in educating individuals and their families about matters related to primary hyperoxaluria type 1 (PH1). PELs can help you in a variety of ways, including providing disease and product education, connecting you to additional resources, and answering questions about treatment with OXLUMO. PELs are employees of Alnylam Pharmaceuticals. They are not acting as healthcare providers and are not part of your healthcare team. Learn about the PEL team and how to get connected ›

What additional resources are available?

In addition to the personalized services that are part of Alnylam Assist™, there are also educational and support resources for patients and their families. These include downloadable materials about PH1 and treatment with OXLUMO, as well as links to advocacy groups that connect patients to the PH1 community. Find out what’s available to support you and your family ›

What if I'm a caregiver?

Alnylam Assist™ is here to support you, too. While our program helps with everything from figuring out insurance to learning more about PH1, we can also connect you to organizations that can offer additional resources ›

How can I contact Alnylam Assist?

Your Case Manager from Alnylam Assist™ is available from 8am - 6pm ET, Monday - Friday at 1-833-256-2748.

Alnylam Assist® get started icon

See How to Get Started

Once you and your doctor decide to begin treatment with OXLUMO, we'll work with your healthcare team to start the process.

How to Get Started

Alnylam Assist® Case Manager Kevin

Call Kevin


Monday - Friday, 8am - 6pm ET

Alylam Separator Triangles


The most common side effect of OXLUMO® (lumasiran) is injection site reaction (redness, pain, itching, and swelling at the site of injection). These are not all the possible side effects of OXLUMO. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

OXLUMO has not been studied in pregnant or breastfeeding women. Talk to your doctor about the risk of taking OXLUMO if you are pregnant, plan to become pregnant, are breastfeeding, or plan to breastfeed.


OXLUMO is a prescription medicine for the treatment of primary hyperoxaluria type 1 (PH1) to lower oxalate in urine in children and adults.

For additional information about OXLUMO, please see the full Prescribing Information.